Heidelberg (pta027/10.02.2021/15:32) - 4basebio AG (Frankfurt: 2INV; ISIN: DE000A2YN801; Prime Standard), has closed its 2020 financial year (01.01.2020 to 31.12.2020) with an expected net profit (individual financial statements in accordance with HGB) of EUR 55,075 thousand (previous year: EUR -32,832 thousand).
The preliminary annual result includes other operating income of EUR 68,351 thousand (previous year: EUR 9 thousand) as well as personnel expenses of EUR 233 thousand (previous year: EUR 274 thousand), other operating expenses of EUR 2,162 thousand (previous year: EUR 1,800 thousand), depreciation of EUR 9,715 thousand (previous year: EUR 31,610 thousand) and a financial result of EUR -1,129 thousand (previous year: EUR 643 thousand).
Other operating income mainly includes (EUR 66,863 thousand) income from the Abcam transaction. 4basebio AG (at that time still: Expedeon AG) sold its immunology and proteomics business units for a purchase price of EUR 120 million in cash to Abcam plc (Cambridge, UK) and its subsidiary Abcam Inc. (Cambridge, MA, USA) (the "Abcam Transaction"). The Abcam Transaction involved the sale and transfer of all of the shares in Expedeon Holdings Ltd. (Cambridge, UK) to Abcam plc and certain assets of its subsidiary Expedeon Inc. (San Diego, CA, USA) to Abcam Inc.
Other operating expenses mainly include legal and consulting costs (EUR 765 thousand), accounting and auditing costs (EUR 382 thousand) and capital market communication costs (EUR 343 thousand). The financial result amounts to EUR -1,129 thousand.
The preliminary balance sheet as of 31 December 2020 according to the German Commercial Code (HGB) shows equity of EUR 84,757 thousand (previous year: EUR 45,991 thousand).
4basebio AG spun-off the entire operating business that remained after the Abcam Transaction with 4basebio AG Group, namely the genomics and DNA manufacturing businesses operated through the wholly-owned subsidiaries 4basebio S.L.U. and 4basebio LTD (together the "Genomics & DNA Business"), by transferring all of the shares in 4basebio S.L.U. and 4basebio LTD by way of a spin-off pursuant to the German Transformation Act (Abspaltung zur Aufnahme pursuant to § 123 para. 2 no. 1 UmwG) to 4basebio SE, which was acquired for this purpose and was previously non-operational (the "Spin-off"). Prior to the Spin-off, 4basebio AG increased the capital of 4basebio LTD by cash contribution in the amount of approximately EUR 8.1 million against the issuance of the new 4basebio LTD shares and made an additional payment of approximately EUR 13.1 million into the capital reserves of 4basebio S.L.U. in order to strengthen the respective equity of the spun-off subsidiaries.
Furthermore, 4basebio AG carried out a capital increase against a cash contribution of approximately EUR 4.3 million at 4basebio SE before the spin-off became effective. After the cash capital increase, 4basebio AG held a total of 3,695,242 shares in 4basebio SE. In order to carry out the spin-off, 4basebio SE increased its share capital from then EUR 3,695,242 by a further EUR 8,622,231 to EUR 12,317,473 by issuing a further 8,622,231 no-par value registered shares, which were allocated to the shareholders of 4basebio AG as consideration for the transfer of the Genomics & DNA Business. After the spin-off, 4basebio AG thus holds a direct minority interest in 4basebio SE, which will be listed in the future, with a total share of approx. 30% of the share capital. The remaining shareholders hold approx. 70% of the shares in 4basebio SE.
Immediately after the spin-off became effective, the registered office of 4basebio SE was transferred to Cambridge, England, United Kingdom and now operates under the name 4basebio UK Societas. The shares of 4basebio UK Societas are expected to be admitted to trading on the London Stock Exchange (Alternative Investment Market segment) on 17 February 2021.
Accordingly, the balance sheet as of 31 December 2021 now only includes a circa 30% stake in 4basebio UK Societas and no longer includes any operating business.
The aforementioned preliminary result is based on the preliminary valuation of the past 2020 financial year made by the Executive Board on 10 February 2021. The figures stated in this announcement are subject to the final preparation of the annual financial statements, the audit of the financial statements and the approval of the annual financial statements by the Supervisory Board.
About 4basebio AG:
4basebio AG (renamed 2invest AG by resolution of the Annual General Meeting on 28 January 2021) is a listed company that acquires, holds, manages and sells investments in corporations and partnerships, in particular - but not exclusively - in the biotechnology, life science and IT sectors in Germany and abroad.
Global investments or investments in unlisted companies or financial instruments are also possible. Investment decisions are made on the basis of attractive risk-reward profiles. The focus is on achieving a risk-adequate, long-term total return. The company is listed in the Prime Standard of the Frankfurt Stock Exchange (Ticker: 2INV; ISIN: DE000A2YN801). More information: www.4basebioag.com
For further information please contact:
Board of Directors
Dr Robert Mayer, Manager IR
Tel: +49 171 3876540
# # # This publication is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements contained in this press release that do not relate to proven financial results or other historical data should be considered forward-looking, meaning that such statements are primarily predictions of future results, trends, plans or objectives. These statements should not be considered as total guarantees because, by their nature, they are subject to known and unknown risks and uncertainties and may be affected by other factors that could cause 4basebio AG's actual results, plans and objectives to differ materially from any stated conclusions or implied predictions contained in such statements. 4basebio undertakes no obligation to publicly update or revise any of these statements, whether as a result of new information, future results or otherwise. # #(end)
Ziegelhäuser Landstr. 3
|contact person:||Robert Mayer|
|phone:||+49 171 3876540|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|